- Home
- AMSF vs RIGL Comparison
AMSF vs RIGL Comparison
Compare AMSF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | RIGL |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 564.7M |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AMSF | RIGL |
|---|---|---|
| Price | $33.81 | $40.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $46.33 | $45.67 |
| AVG Volume (30 Days) | 218.0K | ★ 386.8K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 0.43 | ★ 0.44 |
| Revenue | ★ $317,252,000.00 | $294,282,000.00 |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | $12.75 |
| P/E Ratio | ★ $77.97 | $94.93 |
| Revenue Growth | 2.66 | ★ 64.15 |
| 52 Week Low | $29.42 | $18.81 |
| 52 Week High | $47.86 | $52.24 |
Technical Indicators
Market Signals| Indicator | AMSF | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 62.42 |
| Support Level | $32.11 | $40.05 |
| Resistance Level | $34.15 | $44.42 |
| Average True Range (ATR) | 1.01 | 1.90 |
| MACD | -0.17 | -0.23 |
| Stochastic Oscillator | 37.70 | 45.33 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.